Status:

COMPLETED

Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

Lead Sponsor:

Rigshospitalet, Denmark

Conditions:

Endometriosis

Eligibility:

FEMALE

20-40 years

Phase:

PHASE4

Brief Summary

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Eligibility Criteria

Inclusion

  • Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
  • Couples with indication and wish for IVF/ICSI
  • Age of women: 20-40 years
  • Regular menstrual cycle within normal range (21-35 days)
  • Body Mass Index (BMI): 18-30 kg/m2

Exclusion

  • History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
  • Treatment of endometriosis with GnRH agonist during the last 3 month

Key Trial Info

Start Date :

January 1 2005

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00286351

Start Date

January 1 2005

Last Update

April 23 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet

Copenhagen, Copenhagen East, Denmark, 2100

Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis | DecenTrialz